Teva’s merger strains domestic pharmaceutical sector
Published: 2012-11-08 06:59:00
Updated: 2012-11-08 06:59:00
The rumors that Teva Pharmaceuticals will acquire major stocks of Korea’s mid-tier pharmaceutical firm have strained the pharmaceutical industry here, as Teva is the world's leading generic drug manufacturer known for its hostile takeover bids.
However, industry officials have suspicioned that...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
